1. Introduction {#sec1-jcm-09-02310}
===============

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective anti-leukemic therapy for adults with acute leukemia. However, only about 30% of the patients have a human leukocyte antigen (HLA) identical sibling and additional 40%--50% matched unrelated donors; thus, many require an alternative donor. Two major alternative donor sources include haplo-identical donors and cord blood transplantation (CBT). Recent studies have established CBT as a valuable alternative to bone marrow transplantation in adults without readily available donors \[[@B1-jcm-09-02310],[@B2-jcm-09-02310],[@B3-jcm-09-02310],[@B4-jcm-09-02310]\]. The immediate availability and the more leniently tolerated levels of HLA disparity in this setting, along with encouraging results showing better graft-versus-leukemia effects of CBT compared to HLA-matched or -mismatched unrelated donors \[[@B5-jcm-09-02310],[@B6-jcm-09-02310],[@B7-jcm-09-02310],[@B8-jcm-09-02310]\], offer great advantages. On the other hand, the limited number of total nucleated cells (TNC) and low immunogenicity of the cells has been associated with slower hematopoietic and immune reconstitution \[[@B9-jcm-09-02310],[@B10-jcm-09-02310]\]. Furthermore, the lack of prospective trial results raises contentions over optimal conditioning regimen and graft-versus-host disease (GVHD) prophylaxis during CBT.

Recognizing the paucity of data on CBT from Korea, we conducted this retrospective study to investigate the feasibility of CBT for adult patients with acute leukemia with special regards to the impact of different conditioning and GVHD prophylaxis regimens on clinical outcomes.

2. Materials and Methods {#sec2-jcm-09-02310}
========================

2.1. Study Design and Subjects {#sec2dot1-jcm-09-02310}
------------------------------

This was a multicenter, longitudinal cohort study of patients over 18 years old undergoing CBT. The study period was set between January 2001 and May 2019. A total of 95 patients were screened, and after elimination as shown in [Figure 1](#jcm-09-02310-f001){ref-type="fig"}, a total of 70 patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) were deemed eligible ([Figure 1](#jcm-09-02310-f001){ref-type="fig"}). Their medical records were reviewed for demographics, response to treatment, factors related to CBT, and survival outcomes. This study was conducted according to the Declaration of Helsinki and was approved by the Institutional Review Board of each of the 16 participating hospitals. All authors had access to the study data and reviewed and approved this study.

2.2. HLA Typing and Donor Selection {#sec2dot2-jcm-09-02310}
-----------------------------------

Donor-recipient matching considered lower resolution HLA matching at HLA-A and --B (antigen-level) and allele-level at HLA-DRB1. When double units were used, the transplant was assigned the lowest unit-recipient HLA-mismatch. In Korea, transplantation with CB units of 0 to 2 HLA antigen mismatches with the patient is recommended, but per physician's decision 3/6 HLA matched CB unit can be used. Furthermore, the recommended minimum number of total nucleated cells (TNC) is 3.0 × 10^7^/kg of patient body weight at cryopreservation for malignancies. ABO incompatibility was not incorporated as one of the factors used in CB unit selection.

2.3. Conditioning Regimen and GVHD Prophylaxis {#sec2dot3-jcm-09-02310}
----------------------------------------------

The conditioning regimens were divided into 4 groups: Group 1, reduced intensity conditioning (RIC) without total body irradiation (TBI); Group 2, RIC with TBI; Group 3, myeloablative conditioning (MAC) without TBI; Group 4, MAC with TBI. The conditioning regimens used for Group 1 (*n* = 14) consisted of the following: fludarabine plus busulfan (FluBu, *n* = 12) administered over 2 to 3 days, or, fludarabine plus melphalan (FluMel, *n* = 2). The regimen for Group 2 (*n* = 11) was fludarabine plus cyclophosphamide (FluCy) with TBI. The regimens used for Group 3 (*n* = 13) consisted of busulfan plus cyclophosphamide (BuCy, *n* = 3), thiotepa plus FluBu administered over 4 days (*n* = 3), and busulfan/melphalan/fludarabine (BuFluMel, *n* = 7). Finally, the regimen for Group 4 (*n* = 31) included TBI/cyclophosphamide plus fludararbine, etoposide or cytarabine.

GVHD prophylaxis regimens included cyclosporine (CsA), methotrexate (MTX), mycophenolate mofetil (MMF), tacrolimus, and antithymocyte globulin (ATG). Tapering of immunosuppressants was initiated at 2--4 months after transplantation, with the goal of cessation by approximately 6 months in the absence of GVHD. Supportive care after transplantation, including empirical antibiotics use, cytomegalovirus (CMV) prophylaxis and hepatic sinusoidal obstruction syndrome (SOS) prevention, was performed according to each institutional protocol.

2.4. Definitions {#sec2dot4-jcm-09-02310}
----------------

Neutrophil engraftment was defined as an absolute neutrophil count (ANC) \> 0.5 × 10^9^/L for 3 consecutive days. Platelet recovery was defined as platelet count \> 20.0 × 10^9^/L for 7 consecutive days without transfusion. Acute GVHD grading was performed according to the standard criteria \[[@B11-jcm-09-02310]\]. Chronic GVHD was classified as mild, moderate, or severe according to the 2014 National Institutes of Health consensus criteria \[[@B12-jcm-09-02310]\]. Treatment-related mortality (TRM) was defined as death without progression of underlying acute leukemia. Relapse was defined by the morphologic evidence of disease in the peripheral blood, bone marrow, or extra-medullary sites. The relapse free survival (RFS) was defined as the time from stem cell infusion to relapse or death from any cause. The overall survival (OS) was defined as the time from stem cell infusion to death of any cause.

2.5. Statistical Analysis {#sec2dot5-jcm-09-02310}
-------------------------

Differences between groups were assessed using a Student's t-test or one-way analysis of variance for continuous variables, and Pearson chi-square test for categorical variables, as indicated. The RFS and OS curves were estimated using the Kaplan--Meier method. If patients survived without death or progression, the survival was censored at the latest date of follow-up when no death or progression was confirmed. These data were analyzed using the Statistical Package for the Social Sciences software (IBM^®^ SPSS^®^ Statistics, version 22.0); *p*-values of \<0.05 were considered statistically significant.

Cumulative incidence curves were used in competing-risk setting to calculate the probability of neutrophil and platelet engraftment, acute and chronic GVHD, and TRM. For neutrophil and platelet engraftment, death before recovery was considered as the competing events. For GVHD, death without an event was considered as the competing event. For TRM, relapse was considered as the competing event. For this part of the analyses, SAS Enterprise Guide 6.1 Version and the statistical software R ([www.r-project.org](www.r-project.org)) were used. Associations between potential prognostic factors and survival outcomes were evaluated using the Cox's proportional hazard regression models. The following variables were considered as covariates: age at CBT, year of CBT, body weight, duration from diagnosis to CBT, HLA-mismatch, infused TNC and CD34+ cell dose, status of underlying disease at CBT, conditioning regimens, and GVHD prophylaxis. A stepwise backward procedure was used, and predictors achieving a *p*-value below 0.10 were considered then sequentially removed if the *p*-value in the multiple model was above 0.05.

3. Results {#sec3-jcm-09-02310}
==========

3.1. Patients {#sec3dot1-jcm-09-02310}
-------------

The baseline characteristics of 41 AML and 29 ALL patients are shown in [Table 1](#jcm-09-02310-t001){ref-type="table"}. The number of CBT cases increased over time for both AML and ALL. The median age at CBT was 47 years (range 22--66) for AML patients and 29 years (range 18--64) for ALL patients. The median time from diagnosis to transplantation was 7 months (range 2--85), and the median TNC was 2.5 × 10^7^/kg (range 1.0--5.2) and the median CD34 + cells 1.0 × 10^5^/kg (range 0.1--4.1).

3.2. Engraftment {#sec3dot2-jcm-09-02310}
----------------

Fifty-five patients (78.6%) out of 70 achieved primary neutrophil engraftment at a median of day 22 (range 8--74) ([Table 2](#jcm-09-02310-t002){ref-type="table"}). The cumulative incidence of neutrophil engraftment was 73.7% at day 22. Among the 15 patients who did not achieve neutrophil engraftment, 12 died and 3 survived without neutrophil engraftment. Generally, there was no difference between RIC conditioning versus MAC conditioning with regards to neutrophil engraftment (RIC 76% vs. MAC 80%, *p* = 0.696). More specifically, for AML patients the neutrophil engraftment was observed in 87.5% of RIC and 72.0% of MAC group (*p* = 0.242). For ALL patients, neutrophil engraftment was observed in 55.6% of RIC and 90.0% of MAC group (*p* = 0.034). The median time to platelet recovery was 46 days (range 15--182). The cumulative incidence of platelet engraftment was 88.2% by day 46. There was no difference in platelet recovery rates with regards to acute leukemia subtype or conditioning intensity.

3.3. GVHD {#sec3dot3-jcm-09-02310}
---------

As shown in [Table 2](#jcm-09-02310-t002){ref-type="table"}, the cumulative incidence of any acute GVHD at day 100 for the entire cohort was 33.5%, and the cumulative incidence of grades II-IV acute GVHD was 24.7%. For AML patients, the cumulative incidence of any acute GVHD at day 100 was 29.3% and grades II-IV 26.8%. The cumulative incidence of severe acute GVHD (grades III and IV) was 12.2%. For ALL patients, the cumulative incidence of any acute GVHD at day 100 was 39.9% and grades II-IV 21.7%. The cumulative incidence of severe acute GVHD was 3.6%.

The cumulative incidence of any chronic GVHD at 1 year was 17.8%, and the cumulative incidence of moderate to severe chronic GVHD was 3.2%. ALL patients showed trends towards more frequent incidence of chronic GVHD compared to AML patients ([Table 2](#jcm-09-02310-t002){ref-type="table"}) but the difference did not reach statistical difference (for any chronic GVHD, *p* = 0.218; for moderate to severe chronic GVHD, *p* = 0.677).

3.4. Complications other than GVHD {#sec3dot4-jcm-09-02310}
----------------------------------

At day 100, infections were documented in 45 patients (64.3%). They included bacterial (*n* = 34, 75.6%), fungal (*n* = 6, 13.3%), and viral infection (*n* = 5, 11.1%). Infection rates were not different (*P* = 0.305) between ATG users (55.0%, *n* = 11/20) versus ATG non-users (68.0%, *n* = 34/50). CMV antigenemia was detected in 45 patients (65.2%). Among them, 12 AML patients and 2 ALL patients had overt CMV disease. SOS occurred in three patients: one ALL patient who was conditioned with TBI/Cy died from complications related to SOS, while two AML patients (one undergoing TBI/Cy + cytarabine conditioning, and the other Bu/Flu/Mel) recovered.

The cumulative incidence of TRM at Day 100 was 29.2%, and at year 1, 36.9%. A total of 28 patients died from TRM at a median of 70 days (range 9--1110). Causes of death included infection (*n* = 23), SOS (*n* = 1), heart failure (*n* = 2), acute respiratory distress syndrome (*n* = 1), and post-transplant lymphoproliferative disease (*n* = 1).

3.5. Relapse free Survival and overall survival of AML {#sec3dot5-jcm-09-02310}
------------------------------------------------------

The median RFS was 5 months and OS 7 months for AML patients. The 3-year RFS was 36.6% and 3-year OS 36.6%. Conditioning regimen did not affect RFS ([Figure 2](#jcm-09-02310-f002){ref-type="fig"}a) or OS ([Figure 2](#jcm-09-02310-f002){ref-type="fig"}b). GVHD prophylaxis using calcineurin inhibitors (CNI) plus MTX was associated with better RFS (median not reached) compared to CNI plus ATG (median 3 months, *p* = 0.032), as shown in [Figure 3](#jcm-09-02310-f003){ref-type="fig"}a. CNI plus MTX used also showed longest OS ([Figure 3](#jcm-09-02310-f003){ref-type="fig"}b) but the difference did not reach statistical significance.

As shown in [Table 3](#jcm-09-02310-t003){ref-type="table"}, multivariate analyses showed that the year of CBT and GVHD prophylaxis regimen were associated with RFS. Only the year of CBT was identified as prognostic factor for OS. The conditioning regimen did not affect survivals in AML. Double unit CB showed slightly better outcomes compared to single unit CB, but the difference was not statistically significant.

3.6. Relapse Free Survival and Overall Survival of ALL {#sec3dot6-jcm-09-02310}
------------------------------------------------------

The median RFS was 5 months and OS 19 months for ALL patients. The 3-year RFS was 41.1% and 3-year OS 44.8%. Generally, MAC regimens were associated with better RFS ([Figure 2](#jcm-09-02310-f002){ref-type="fig"}a). Especially, TBI-based MAC regimen was associated with both longer RFS and OS compared to other conditioning regimens. As in AML, ATG use was associated with worse survival in ALL ([Figure 3](#jcm-09-02310-f003){ref-type="fig"}). GVHD prophylaxis with CNI only was associated with best survival outcomes.

Multivariate analyses identified the year of CBT, conditioning regimen, GVHD, and prophylaxis regimen as prognostic factors for RFS. Meanwhile, only conditioning regimen was recognized as prognostic factors for OS ([Table 3](#jcm-09-02310-t003){ref-type="table"}).

4. Discussion {#sec4-jcm-09-02310}
=============

With the nuclear family becoming the dominant family unit, the interest in alternative donor sources for HSCT is growing. The present study provides evidence that CB is a good alternative cell source for adult acute leukemia patients with low incidence of GVHD. Furthermore, we found that individualized preparative regimens can improve the outcomes of CBT. More specifically, we found that (1) in line with previous reports \[[@B13-jcm-09-02310],[@B14-jcm-09-02310]\], ATG should be used with caution during CBT; (2) incorporation of MTX may be beneficial; and (3) the use of MAC conditioning, especially TBI-based, for ALL improves survival outcomes, while there was no difference between MAC and RIC conditioning regimens for AML.

The AML patients in the present study tended to be older than the ALL patients, but considering that median age of AML onset is 68, our patients with median age of 47 (range 22--66) represent relatively fit patient population. Even so, MAC conditioning regimens did not necessarily yield better outcomes compared to RIC conditioning regimens ([Figure 2](#jcm-09-02310-f002){ref-type="fig"}). Due to concerns over engraftment issues, initial adult CBT were carried out with MAC conditioning. However, after the introduction of Minnesota group's regimen \[[@B15-jcm-09-02310],[@B16-jcm-09-02310],[@B17-jcm-09-02310]\], the use of RIC conditioning is increasing and, accordingly, 39% of our AML patients also underwent RIC conditioning. The neutrophil engraftment was noted in 78% of the AML patients at a median of 21 days. More importantly, there were no difference between patients undergoing RIC conditioning versus MAC conditioning. For AML patients undergoing RIC conditioning, the neutrophil engraftment rate was 87.5% at a median of 19.5 days, which is similar to previous studies reporting neutrophil recovery ranging from 76% to 85% \[[@B15-jcm-09-02310],[@B18-jcm-09-02310]\]. For those undergoing MAC conditioning, neutrophil recovery was seen in 72% at a median of 21 days. Furthermore, the 3-year RFS for our AML patients was 36.6%, which is comparable to previous studies reporting 3-year RFS ranging from 28% to 38% \[[@B15-jcm-09-02310],[@B17-jcm-09-02310],[@B18-jcm-09-02310],[@B19-jcm-09-02310]\], suggesting that myelo-ablation is not absolutely necessary and conditioning regimen can be chosen based on the condition of the recipient for AML.

The cumulative incidence of grades II-IV acute GVHD at Day 100 was 26.8%, which is comparable to previous reports and significantly less than HSCT from other alternative sources \[[@B17-jcm-09-02310],[@B20-jcm-09-02310]\]. Interestingly, the use of MTX was associated with better survival outcomes ([Figure 3](#jcm-09-02310-f003){ref-type="fig"}). Traditionally in the United States and Europe, the use of MTX have been avoided due to the concern of engraftment \[[@B21-jcm-09-02310]\]. On the other hand, there is evidence supporting the use of MTX from Japan \[[@B22-jcm-09-02310],[@B23-jcm-09-02310],[@B24-jcm-09-02310],[@B25-jcm-09-02310]\]. In these Japanese studies, the use of MTX led to reduced pre-engraftment immune reactions, engraftment syndromes, acute GVHD, and TRM while improving RFS in both children and adults. Since Koreans are ethnically similar to Japanese, the use of MTX indeed could be beneficial but the number of patients in the present study is too small and the administration schedule too heterogeneous to firmly determine the benefits of MTX addition. On the other hand, the use of ATG warrants more caution. Although there are no large comparative studies, since CBT is a naturally T-cell depleted HSCT, the use of ATG during CBT has been traditionally associated prolonged T lymphopenia and subsequently higher infection rates \[[@B13-jcm-09-02310],[@B14-jcm-09-02310],[@B26-jcm-09-02310]\]. In our study, there was no difference in infection rates between ATG-users versus non-users but the use of ATG was identified as an adverse prognostic factor for survival ([Table 3](#jcm-09-02310-t003){ref-type="table"}), advocating avoidance of its use during CBT.

For ALL, the results were a bit different. The RFS, OS, and cumulative incidence of acute GVHD in our ALL patients were similar to results of previous reports \[[@B27-jcm-09-02310],[@B28-jcm-09-02310],[@B29-jcm-09-02310]\]. In our cohort, MAC conditioning was associated with trends towards better survival outcomes ([Figure 2](#jcm-09-02310-f002){ref-type="fig"}) and TBI-based MAC conditioning seemed especially beneficial. To the best of our knowledge, this is the first report showing the superiority of TBI-based MAC conditioning in CBT setting for adult ALL. This comes as no surprise, however, as TBI-based MAC conditioning has been consistently associated with better survival outcomes in ALL \[[@B30-jcm-09-02310],[@B31-jcm-09-02310],[@B32-jcm-09-02310]\]. More meticulously executed prospective trials should ensue for confirmation of this particular finding. As for GVHD prophylaxis, the used of ATG was associated with negative survival outcomes in ALL as in AML.

The advantage of single versus double CBT in adults is theoretical. Double CBT has shown improved 2-year survival with double CBT (62%) compared to single CBT (47%) in some reports \[[@B33-jcm-09-02310]\], but a randomized study failed to prove the superiority \[[@B21-jcm-09-02310]\]. Rather, the extent of HLA match and CB TNC dose seem to navigate the success of CBT \[[@B34-jcm-09-02310]\]. In our study, most patients underwent double CBT to meet the recommended minimum number of TNC (3.0x10^7^/kg), but there were no survival differences between single CBT group versus double CBT group.

One of the most obvious limitations of this study is the retrospective nature. Furthermore, although 70 cases of CBT is not a trivial number considering the fact that the use of CBT is not as widespread, it is perhaps a little small to draw statistically powerful conclusions. However, the advantage of using Korean population is that because Korea has a single public medical insurance system that covers approximately 98% of the overall Korean population \[[@B35-jcm-09-02310]\]. The range of coverage is strictly controlled; thus, the general leukemia treatment algorithm is relatively uniform throughout the population. This, in turn, ensures the quality of data. Lastly, since the duration of the study period spans from year 2000 to 2019, many aspects of acute leukemia diagnosis and treatment, including risk stratification, use of target therapies, supportive care, have altered over the course of time. However, if anything, from the results of CBT are improving as seen in [Figure 4](#jcm-09-02310-f004){ref-type="fig"}, we can safely assume that such changes had positive effects. All in all, these limitations do not diminish the importance of our findings that can be readily incorporated into real-world practice.

5. Conclusions {#sec5-jcm-09-02310}
==============

In conclusion, we provide evidence that CBT is a readily available option worth considering for adult acute leukemia patients. The results of CBT are improving, but there is still room for improvement with regards to patient selection and optimal preparative regimen. Individualized conditioning regimens will add value in terms of enhancing safety and efficacy, and in the absence of established guidelines, this study provides aid for physicians in selecting appropriate preparative regimens.
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Survival according to graft-versus-host disease (GVHD) prophylaxis regimen.

![](jcm-09-02310-g003a)

![](jcm-09-02310-g003b)

![Relapse free survival (**left**) and overall survival (**right**) over time.](jcm-09-02310-g004){#jcm-09-02310-f004}

jcm-09-02310-t001_Table 1

###### 

Baseline characteristics.

  -----------------------------------------------------------------------------------------------------------------------
                                                             All\             AML\             ALL\             *P*
                                                             *N* = 70 (%)     *N* = 41 (%)     *N* = 29 (%)     
  ---------------------------------------------------------- ---------------- ---------------- ---------------- ---------
  **Age at transplantation, years (median, range)**          44 (18--66)      47 (22--66)      29 (18--64)      \<0.001

  **Sex, male**                                              35 (50.0)        18 (43.9)        17 (58.6)        0.225

  **Body weight, kg (median, range)**                        59.5 (43--98)    60 (43--90)      58 (45--98)      0.787

  **Diagnosis to transplantation, months (median, range)**   7 (2--85)        9 (3--85)        7 (2--76)        0.425

  **Transplantation period**                                                                                    

  2001--2004                                                 5 (7.1)          4 (9.8)          1 (3.4)          0.542

  2005--2009                                                 17 (24.3)        9 (22.0)         8 (27.6)         

  2010--2014                                                 20 (28.6)        10 (24.4)        10 (34.5)        

  2015--2019                                                 28 (40.0)        18 (43.9)        10 (34.5)        

  **Disease status at transplantation**                                                                         

  CR1                                                        43 (61.4)        24 (58.5)        19 (65.5)        0.195

  CR2                                                        13 (18.6)        6 (14.6)         7 (24.1)         

  Others\*                                                   14 (20.0)        11 (26.8)        3 (10.3)         

  **Conditioning regimen**                                                                                      

  Myeloablative                                                                                                 

  TBI containing                                             31 (44.3)        16 (39.0)        15 (51.7)        0.608

  Non-TBI containing                                         14 (20.0)        9 (22.0)         5 (17.2)         

  Reduced intensity                                                                                             

  TBI containing                                             11 (15.7)        6 (14.6)         5 (17.2)         0.600

  Non-TBI containing                                         14 (20.0)        10 (24.4)        4 (13.8)         

  **GVHD prophylaxis**                                                                                          

  CNI + ATG                                                  11 (15.7)        7 (17.1)         4 (13.8)         0.804

  CNI + MTX                                                  20 (28.6)        10 (24.4)        10 (34.5)        

  CNI + MTX + ATG                                            9 (12.9)         6 (14.6)         3 (10.3)         

  CNI only                                                   30 (42.9)        18 (43.9)        12 (41.4)        

  **Infused cord blood**                                                                                        

  Total nucleated cells, 10^7^/kg (median, range)            2.5 (1.0--5.2)   2.4 (1.0--5.2)   2.5 (1.0--4.1)   0.947

  CD34+ cells, 10^5^/kg (median, range)                      1.0 (0.1--4.1)   1.2 (0.1--4.1)   1.0 (0.1--2.7)   0.413

  **Single unit HLA matching (*N* = 13)**                                                                       

  6/6                                                        1 (7.7)          1 (10.0)         0                0.557

  5/6                                                        2 (15.4)         1 (10.0)         1 (33.3)         

  4/6                                                        10 (76.9)        8 (80.0)         2 (66.7)         

  **Double unit HLA matching (*N* = 57)**                                                                       

  4/6 + 4/6                                                  8 (14.0)         6 (19.4)         2 (7.7)          0.443

  5/6 + 5/6                                                  18 (31.6)        12 (38.7)        6 (23.1)         

  6/6 + 6/6                                                  5 (8.8)          2 (6.5)          3 (11.5)         

  6/6 + 5/6                                                  2 (3.5)          0                2 (7.7)          

  6/6 + 4/6                                                  2 (3.5)          1 (3.2)          1 (3.8)          

  6/6 + 3/6                                                  1 (1.8)          0                1 (3.8)          

  5/6 + 4/6                                                  19 (33.3)        9 (29.0)         10 (38.5)        

  5/6 + 3/6                                                  2 (3.5)          1 (3.8)          1 (3.8)          

  **ECOG performance status at transplantation**                                                                

  0                                                          22 (31.4)        13 (31.7)        9 (31.0)         0.747

  1                                                          41 (58.6)        23 (56.1)        18 (62.1)        

  2                                                          7 (10.0)         5 (12.2)         2 (6.9)          
  -----------------------------------------------------------------------------------------------------------------------

AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, CR1: first complete remission, CR2: a complete remission, TBI: total body irradiation, GVHD: graft-versus-host disease, CNI: calcineurin inhibitor, ATG: anti-thymoglobulin, MTX: methotrexate, HLA: human leukocyte antigen, ECOG: Eastern Cooperative Oncology Group. Others include CR beyond CR2 (CR3, CR4 and so forth) and salvage HSCT in refractory settings.

jcm-09-02310-t002_Table 2

###### 

Transplantation outcomes.

  --------------------------------------------------------------------------------------------------------
                                                              All\           AML\           ALL\
                                                              *N* = 70 (%)   *N* = 41 (%)   *N* = 29 (%)
  ----------------------------------------------------------- -------------- -------------- --------------
  **Neutrophil engraftment**                                  55 (78.6)      32 (78.0)      23 (79.3)

  Time to neutrophil engraftment, days (median, range)        22 (8--74)     21 (8--64)     26 (11--74)

  **Platelet recovery**                                       46 (65.7)      27 (65.9)      19 (65.5)

  Time to platelet recovery, days (median, range)             41 (15--182)   39 (15--182)   46 (20--131)

  **Cumulative incidence of any acute GVHD at Day 100 \***    33.5           29.3           39.9

  Grade II-IV acute GVHD                                      24.7           26.8           21.7

  **Cumulative incidence of any chronic GVHD at 1 year \***   17.8           13.5           24.5

  Moderate-severe chronic GVHD                                3.2            2.5            4.4

  **Any infection**                                           45 (64.3)      28 (68.3)      17 (58.6)

  Bacterial ^†^                                               34 (75.6)      19 (70.4)      15 (83.3)

  Fungal ^†^                                                  6 (13.3)       5 (18.5)       1 (5.6)

  Viral ^†^                                                   5 (11.1)       3 (11.1)       2 (11.1)

  **CMV antigenemia**                                         45 (65.2)      31 (75.6)      14 (48.3)

  Pneumonitis                                                 5              4              1

  Retinitis                                                   4              4              0

  GI tract infection                                          5              4              1

  **Cumulative incidence of TRM at Day 100 \***               29.2           29.3           28.9

  **Cumulative incidence of TRM at 1 year \***                36.9           39.5           32.7
  --------------------------------------------------------------------------------------------------------

AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, GVHD: graft-versus-host disease, CMV: cytomegalovirus, GI: gastrointestinal, TRM: treatment-related mortality. \* Represented as % (95% confidence interval range) ^†^ Percentage out of all infections.

jcm-09-02310-t003_Table 3

###### 

Risk factors for transplantation outcomes on multivariate analyses.

                                   Variable                                 HR (95% CI)            *p*
  -------------------------------- ---------------------- ----------------- ---------------------- -------
  **AML, relapse free survival**   Year of CBT            2001--2004        1                      
                                                          2005--2009        0.304 (0.084--1.099)   0.069
                                                          2010--2014        0.285 (0.078--1.044)   0.058
                                                          2015--2019        0.147 (0.040--0.535)   0.004
                                   GVHD prophylaxis       CNI + ATG         1                      
                                                          CNI + MTX         0.260 (0.070--0.968)   0.045
                                                          CNI + ATG + MTX   1.147 (0.349--3.773)   0.822
                                                          CNI only          0.647 (0.240--1.747)   0.391
  **AML, overall survival**        Year of CBT            2001--2004        1                      
                                                          2005--2009        0.325 (0.090--1.168)   0.085
                                                          2010--2014        0.226 (0.058--0.874)   0.031
                                                          2015--2019        0.151 (0.041--0.556)   0.004
  **ALL, relapse free survival**   Conditioning regimen   Group 1           1                      
                                                          Group 2           0.292 (0.053--1.604)   0.157
                                                          Group 3           0.364 (0.072--1.841)   0.222
                                                          Group 4           0.150 (0.033--0.678)   0.014
                                   Year of CBT            2001--2004        1                      
                                                          2005--2009        0.048 (0.003--0.853)   0.039
                                                          2010--2014        0.062 (0.004--1.031)   0.053
                                                          2015--2019        0.012 (0.001--0.267)   0.005
                                   GVHD prophylaxis       CNI + ATG         1                      
                                                          CNI + MTX         0.290 (0.052--1.604)   0.156
                                                          CNI + ATG + MTX   1.107 (0.173--7.068)   0.914
                                                          CNI only          0.150 (0.026--0.873)   0.035
  **ALL, overall survival**        Conditioning regimen   Group 1           1                      
                                                          Group 2           0.183 (0.027--1.243)   0.082
                                                          Group 3           0.398 (0.076--2.069)   0.273
                                                          Group 4           0.189 (0.042--0.857)   0.031

AML: acute myeloid leukemia, CR1: first complete remission, CR2: a complete remission, CBT: cord blood transplantation, GVHD: graft-versus-host disease, CNI: calcineurin inhibitor, ATG.
